In sterling terms, the total proceeds to 3i and funds represent a 2.3x money multiple on their original investment of US$208 million (£113... ...
http://www.indiainfoline.com/Markets/News/3i-makes-a-2.3x-return-on-sale-of-Xellia/5688097800(GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV), today announced that Dr. Bassam Damaj,... ...
http://www.bizwireexpress.com/showstoryGNW.php?storyid=310764ZURICH (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a... ...
http://in.reuters.com/article/2013/05/16/us-actavis-novartis-idINBRE94F0KH20130516?feedType=RSS&feedName=healthThomson Reuters report offers sneak peek into future of U.S. biosimilar market PHILADELPHIA, May 14, 2013 - The IP & Science business of Thomson... ...
http://www.andhranews.net/Business/2013/Amgen-Hospira-Sandoz-Named-Among-Top-20933.htmA recent court ruling enables drug manufacturers to market their own generic versions of the oral contraceptive Yaz, according to Reuters. Irvine... ...
http://www.bizwireexpress.com/showstoryPRWeb.php?storyid=619829